The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Subscribe To Our Newsletter & Stay Updated
